Fragmento

Over the half past century, the leading causes of morbidity and premature death in countries of Latin America (LA) have gradually shifted from the transmissible diseases caused by distinct infectious agents towards the noncommunicable chronic diseases (NCDs). These illnesses account for 71% of premature deaths globally. However, a very high rate of NCDs occurs among the low and middle- income regions of the Americas. In regards to liver diseases, parasitic infections caused by amoeba or Fasciola hepatica have importantly diminished. At current, the obesity epidemic which has extended dramatically in LA as in other regions of the world, has triggered the incidence of metabolic risk factors that are known to have an impact on the liver, such as non-alcoholic fatty liver disease (NAFLD). Furthermore, the “Elimination of Viral Hepatitis by the year 2030” campaign is a global initiative in which the high-income countries could have better feasibility to fulfill out the strategies, yet its implementation in LA remains unclear. Reasons are partly the underestimation of these health problems by the governmental agencies and the lack of political commitment. On the other hand, more evidence-based literature is required to combat hepatitis viruses in LA starting with an update on the molecular epidemiology of hepatitis viruses A-E or even investigating the efficacy of conventional and new HCV direct-acting antiviral drugs among the admixed populations of this region. Furthermore, alcoholic liver disease whether acute or chronic is still far from becoming unimportant in the near future.

Palabras clave:

2018-09-24   |   714 visitas   |   Evalua este artículo 0 valoraciones

Vol. 17 Núm.5. Septiembre-Octubre 2018 Pags. 749-751 Ann Hepatol 2018; 17(5)